Radiopharmaceuticals company Telix Pharmaceuticals has provided its Q4 FY24 trading update, showing sustained revenue growth.

The S&P/ASX 200 Index (ASX: XJO) surged higher this Thursday, soaring up a welcome 1.38% to finish at a flat 8,327 points.

Shares in Neuren Pharmaceuticals rallied in morning trade, after ending Wednesday's session as the worst performing ASX 200 ...

The market didn't like what this stock had to say this morning... The post Why did this $1.4 billion ASX 200 healthcare stock ...

These shares are having a tough time on hump day. But why? The post Why CAR Group, Myer, Neuren, and Yancoal shares are falling today appeared first on The Motley Fool Australia.

Neuren's partner Acadia Pharmaceuticals submits marketing authorisation application in Europe for trofinetide for treatment ...

Neuren Pharmaceuticals' Rett syndrome treatment, trofinetide, is a step closer to receiving regulatory approval in the ...

Another ASX 200 growth share that could generate big returns according to analysts is NextDC. It is a leading provider of ...

A brief financial summary of Neuren Pharmaceuticals Ltd as well as the most significant critical numbers from each of its financial reports. In addition, some financial ratios derived from these ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...